Evdoxia Kyriazopoulou, Karolina Akinosoglou, Eleni Florou, Elli Kouriannidi, Artemis Bogosian, Olga Tsachouridou, Konstantinos N. Syrigos, Nikolaos Gatselis, Haralampos Milionis, Ilias C. Papanikolaou, Styliani Sympardi, Maria Dafni, Antonia Alevizou, Alexia-Vasiliki Amvrazi, Errika Alexandrou, Kyprianos Archontoulis, Katerina Argyraki, Zoi Alexiou, Yakinthi Georgiou, Dimitra Gkogka, Foteini Kyrailidi, Vassiliki Kalyva, Triantafilli Nikolopoulou, Sofia Ioannou, Petros Bakakos, Georgia Karathanassiou, Kyriakos Koklanos, Dionysios-Nikolaos Miletis, Anna-Maria Tili, Lampros Vakkas, Ioanna Vila, Periklis Panagopoulos, Michael Samarkos, George Chrysos, George N. Dalekos, Garyphallia Poulakou, Symeon Metallidis, Evangelos J. Giamarellos-Bourboulis
Int J Antimicrob Agents. 2025 Jan;65(1):107405
DOI: 10.1016/j.ijantimicag.2024.107405Download pdf 🡇
Funding
This study was funded in part by the Hellenic Institute for the Study of Sepsis, in part by Technomar Shipping Company, and in part by Swedish Orphan BioVitrum AB (publ) (Sobi). Sobi provided financial support to the study and anakinra (Kineret®) free of charge under an Investigator Initiated Study Agreement. Sobi was not involved in the design or conduct of the study, data collection and analysis, or preparation of the manuscript.
Keywords: COVID-19; suPAR; Anakinra; Severe respiratory failure; Mortality